AKT1 and acute myeloid leukemia: Finally, AML patients exhibited a similar protein expression profile, with a decrease in AKT, mTOR, and ERK proteins and their phosphorylated forms starting 24 h and up to 48 h post-treatment with EAPB02303 (Figure 3B).